2023
Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review
Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P, Rimm D, Burtness B, Kuhar C, Carchman E. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review. Viruses 2023, 15: 2320. PMID: 38140561, PMCID: PMC10748233, DOI: 10.3390/v15122320.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTriple-negative breast cancerCancer typesPredictive significancePrognostic factorsClinical outcomesPrognostic significanceCell carcinomaHuman cancersCervical squamous cell carcinomaNeck squamous cell carcinomaAvailable clinical evidenceCochrane Central RegisterInferior clinical outcomesPositive prognostic factorNegative predictive factorNegative prognostic factorWeb of ScienceCentral RegisterControlled TrialsCervical cancerClinical evidencePredictive factorsPancreatic cancerEligible studies
2001
Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience
Gollerkeri A, Harrold L, Rose M, Jain D, Burtness B. Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience. International Journal Of Cancer 2001, 93: 139-141. PMID: 11391633, DOI: 10.1002/ijc.1295.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionYale Cancer CenterPaclitaxel therapyClinic recordsDecreased LVEFCompletion of paclitaxelPre-existing cardiomyopathyPrior cardiac diseasePrior doxorubicin therapySecond-line agentsCongestive heart failureVentricular ejection fractionUse of paclitaxelEffect of paclitaxelEjection fractionHeart failureCardiac dysfunctionClinical evidenceOutpatient clinicCancer CenterCardiac toxicityDoxorubicin therapyCardiac functionRetrospective analysisMean change